GSK PLC Sponsored ADR $GSK Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 2.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 32,227,615 shares of the pharmaceutical company’s stock after acquiring an additional 889,210 shares during the quarter. Fisher Asset Management LLC’s holdings in GSK were worth $1,390,944,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. TOWER TRUST & INVESTMENT Co lifted its holdings in GSK by 1.3% during the third quarter. TOWER TRUST & INVESTMENT Co now owns 23,195 shares of the pharmaceutical company’s stock valued at $1,001,000 after purchasing an additional 293 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of GSK by 16.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,854 shares of the pharmaceutical company’s stock valued at $123,000 after purchasing an additional 393 shares during the last quarter. HighPoint Advisor Group LLC grew its holdings in shares of GSK by 2.9% during the 3rd quarter. HighPoint Advisor Group LLC now owns 14,893 shares of the pharmaceutical company’s stock worth $643,000 after purchasing an additional 415 shares during the period. Valeo Financial Advisors LLC raised its holdings in GSK by 3.8% in the 2nd quarter. Valeo Financial Advisors LLC now owns 13,079 shares of the pharmaceutical company’s stock valued at $502,000 after buying an additional 478 shares during the period. Finally, Westside Investment Management Inc. lifted its position in GSK by 98.6% in the third quarter. Westside Investment Management Inc. now owns 991 shares of the pharmaceutical company’s stock valued at $45,000 after buying an additional 492 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

NYSE:GSK opened at $59.06 on Monday. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.92. The stock has a market cap of $120.37 billion, a PE ratio of 15.96, a price-to-earnings-growth ratio of 3.58 and a beta of 0.44. GSK PLC Sponsored ADR has a fifty-two week low of $32.38 and a fifty-two week high of $61.69. The firm’s fifty day simple moving average is $53.16 and its 200-day simple moving average is $47.27.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 9th. Investors of record on Friday, February 20th will be paid a $0.4856 dividend. This represents a $1.94 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from GSK’s previous quarterly dividend of $0.42. GSK’s dividend payout ratio is currently 51.62%.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk bought 1,470,000 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was bought at an average price of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the transaction, the insider owned 18,245,691 shares in the company, valued at approximately $346,668,129. The trade was a 8.76% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on GSK shares. Barclays reaffirmed an “underweight” rating on shares of GSK in a research report on Friday, February 20th. TD Cowen reaffirmed a “hold” rating on shares of GSK in a report on Monday, February 9th. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a research note on Wednesday, January 14th. Citigroup restated a “neutral” rating on shares of GSK in a research report on Monday, February 9th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research report on Friday, January 16th. Two analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, GSK has an average rating of “Reduce” and a consensus price target of $44.13.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.